Role of CCR5 and Its Ligands in the Control of Vascular Inflammation and Leukocyte Recruitment Required for Acute Excitotoxic Seizure Induction and Neural Damage
Overview
Affiliations
Chemokines may play a role in leukocyte migration across the blood-brain barrier (BBB) during neuroinflammation and other neuropathological processes, such as epilepsy. We investigated the role of the chemokine receptor CCR5 in seizures. We used a rat model based on intraperitoneal kainic acid (KA) administration. Four months before KA injection, adult rats were given femoral intramarrow inoculations of SV (RNAiR5-RevM10.AU1), which carries an interfering RNA (RNAi) against CCR5, plus a marker epitope (AU1), or its monofunctional RNAi-carrying homologue, SV(RNAiR5). This treatment lowered expression of CCR5 in circulating cells. In control rats, seizures induced elevated expression of CCR5 ligands MIP-1α and RANTES in the microvasculature, increased BBB leakage and CCR5(+) cells, as well as neuronal loss, inflammation, and gliosis in the hippocampi. Animals given either the bifunctional or the monofunctional vector were largely protected from KA-induced seizures, neuroinflammation, BBB damage, and neuron loss. Brain CCR5 mRNA was reduced. Rats receiving RNAiR5-bearing vectors showed far greater repair responses: increased neuronal proliferation, and decreased production of MIP-1α and RANTES. Controls received unrelated SV(BUGT) vectors. Decrease in CCR5 in circulating cells strongly protected from excitotoxin-induced seizures, BBB leakage, CNS injury, and inflammation, and facilitated neurogenic repair.
Guo J, Wang G, Liu T, Zhang J, Li Q, Zhu Y CNS Neurosci Ther. 2025; 31(3):e70246.
PMID: 40019048 PMC: 11868988. DOI: 10.1111/cns.70246.
CHI3L1 in Multiple Sclerosis-From Bench to Clinic.
Jatczak-Pawlik I, Jurewicz A, Domowicz M, Ewiak-Paszynska A, Stasiolek M Cells. 2025; 13(24.
PMID: 39768177 PMC: 11674340. DOI: 10.3390/cells13242086.
Wang W, Ma L, Liu M, Zhao Y, Ye W, Li X Medicine (Baltimore). 2024; 103(22):e38256.
PMID: 39259090 PMC: 11142776. DOI: 10.1097/MD.0000000000038256.
Neuroinflammation in epileptogenesis: from pathophysiology to therapeutic strategies.
Li W, Wu J, Zeng Y, Zheng W Front Immunol. 2024; 14:1269241.
PMID: 38187384 PMC: 10771847. DOI: 10.3389/fimmu.2023.1269241.
Neuroinflammatory mediators in acquired epilepsy: an update.
Chen Y, Nagib M, Yasmen N, Sluter M, Littlejohn T, Yu Y Inflamm Res. 2023; 72(4):683-701.
PMID: 36745211 PMC: 10262518. DOI: 10.1007/s00011-023-01700-8.